Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124
In the published version "Paladini et al. reported that aliskiren 300 mg provided a sustained BP-lowering effect beyond the 24-h dosing interval, with a significantly smaller loss of BP-lowering effect in the 24-48 h period after dose than irbesartan 300 mg or ramipril 10 mg [25]". Paladin...
में बचाया:
मुख्य लेखकों: | Giuseppina Novo (लेखक), Elena Raccuglia (लेखक), Antonino Mignano (लेखक), Salvatore Novo (लेखक), Giovanni Fazio (लेखक) |
---|---|
स्वरूप: | पुस्तक |
प्रकाशित: |
MDPI AG,
2011-09-01T00:00:00Z.
|
विषय: | |
ऑनलाइन पहुंच: | Connect to this object online. |
टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
समान संसाधन
-
Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?
द्वारा: Elena Raccuglia, और अन्य
प्रकाशित: (2009) -
Politics, Peace and Predestination
द्वारा: Hollingworth, Miles
प्रकाशित: (2019) -
Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
द्वारा: Geert Byttebier, और अन्य
प्रकाशित: (2021) -
Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function?
द्वारा: Cody Carson, और अन्य
प्रकाशित: (2016) -
Are ACE inhibitors and ARBs more beneficial than harmful in the treatment of severe COVID-19 disease?
द्वारा: Christian A Devaux
प्रकाशित: (2020)